cis-bis(3-hydroxy-2-methyl-1-methyl-4-pyridinonato)dioxomolybdenum(VI) | 146544-58-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: cis-bis(3-hydroxy-2-methyl-1-methyl-4-pyridinonato)dioxomolybdenum(VI)
• 英文别名: [MoO2(1,2-dimethyl-3-hydroxypyridin-4(1H)-one(-1H))2]
• CAS: 146544-58-3
• 化学式: C₁₄H₁₆MoN₂O₆
• 分子量: 404.231
• InChiKey: RTEXXECZYNGMGQ-UHFFFAOYSA-L

计算性质

• 辛醇/水分配系数(LogP)：
  None
• 重原子数：
  None
• 可旋转键数：
  None
• 环数：
  None
• sp3杂化的碳原子比例：
  None
• 拓扑面积：
  None
• 氢给体数：
  None
• 氢受体数：
  None

反应信息

• 作为产物：
  描述：

  ammonium molybdate 、 1,2-二甲基-3-羟基-4-吡啶酮 以 水 为溶剂， 生成 cis-bis(3-hydroxy-2-methyl-1-methyl-4-pyridinonato)dioxomolybdenum(VI)
  参考文献：
  名称：

  Complexes of 3-hydroxypyridin-2-one and 1,2-dimethyl-3-hydroxypyridin-4-one with second and third row elements of groups 6, 7 and 8

  摘要：

  The syntheses of the 3-hydroxypyridin-2-one (dhpH) and 1,2-dimethyl-3-hydroxypyridin-4-one (dmpH) complexes cis-MoO2L2, cis-W2O5L2, trans-UO2L2, ML3 (M = Fe, Rh), PdL2, [Pd(PPh3)2L]BPh4, ReO(PPh3)L2I (L = dhp, dmp), trans-OsO2(dmp)2, M(dmp)3 (M = Co, Ir), Ru(dmp)3Cl and Fe(dhp)2 are reported. These new complexes have been characterized by their Raman, IR, H-1 and C-13 NMR and (FAB+) mass spectra, and the cyclic voltammograms of some of them recorded.

  DOI：

  10.1016/s0277-5387(00)80167-9

文献信息

• Synthesis, characterization, and biological relevance of hydroxypyrone and hydroxypyridinone complexes of molybdenum
  作者：Sarah J Lord、Noah A Epstein、Robert L Paddock、Christopher M Vogels、Tracy L Hennigar、Michael J Zaworotko、Nicholas J Taylor、William R Driedzic、Tom L Broderick、Stephen A Westcott

  DOI：10.1139/v99-111

  日期：1999.7.1

  We have prepared a number of complexes of the type cis-MoO₂L₂ where L represents a hydroxypyronato or hydroxypyridinonato ligand. Both the maltol (3-hydroxy-2-methyl-4-pyrone, Hma) and kojic acid (5-hydroxy-2-hydroxymethyl-4-pyrone, Hka) complexes, cis-MoO₂(ma)₂ (1) and cis-MoO₂(ka)₂ (2), have been characterized by X-ray diffraction studies. The pyrone ligands are bound to molybdenum in a cis bidentate fashion via the deprotonated hydroxyl groups and the ketone moieties. Crystals of 1 are orthorhombic, a = 12.107 (1), b = 8.6169 (8), c = 16.472 (1) Å, Z = 4, space group Pca2₁, and those of 2 are monoclinic, a = 8.4591 (5), b = 16.3453 (10), c = 10.2954 (7) Å, β = 103.0320 (10)°, Z = 4, space group P2₁/c. Hydroxypyridinone molybdenum complexes have been prepared for both maltol and kojic acid derivatives with the substituents Me, n-Pr, CH₂Ph, Ph at the ring nitrogen. Crystals of the 3-hydroxy-2-methyl-1-phenyl-4-pyridinone (Hppp) derivative, MoO₂(ppp)₂ (9), are monoclinic, a = 10.9476 (6), b = 13.5353 (9), c = 17.4877 (10) Å, β = 93.465 (4)°, Z = 4, space group P2₁/n. Initial investigations into the effects molybdenum compounds have on diabetic hearts are presented. Both Na₂MoO₄ (used as a control) and 1 were effective in lowering blood glucose and free fatty acid levels. Diabetic rats treated with molybdate showed significant improvements in postischemic cardiac function.Key words: molybdenum, hydroxypyrones, hydroxypyridinones, heart function.

  我们已经准备了一系列cis-MoO₂L₂类型的配合物，其中L代表羟基吡啶酮或羟基吡啶酮配体。麦芽酮（3-羟基-2-甲基-4-吡喃酮，Hma）和曲酸（5-羟基-2-羟甲基-4-吡喃酮，Hka）配合物，cis-MoO₂(ma)₂（1）和cis-MoO₂(ka)₂（2），已经通过X射线衍射研究进行了表征。吡喃酮配体以顺式双齿方式通过去质子羟基和酮基与钼结合。1的晶体为正交晶系，a = 12.107（1），b = 8.6169（8），c = 16.472（1）埃，Z = 4，空间群Pca2₁，而2的晶体为单斜晶系，a = 8.4591（5），b = 16.3453（10），c = 10.2954（7）埃，β = 103.0320（10）°，Z = 4，空间群P2₁/c。已经为麦芽酮和曲酸衍生物制备了羟基吡啶酮钼配合物，其在环氮原子处具有Me、n-Pr、CH₂Ph、Ph等取代基。3-羟基-2-甲基-1-苯基-4-吡啶酮（Hppp）衍生物MoO₂(ppp)₂（9）的晶体为单斜晶系，a = 10.9476（6），b = 13.5353（9），c = 17.4877（10）埃，β = 93.465（4）°，Z = 4，空间群P2₁/n。首次研究了钼化合物对糖尿病心脏的影响。钼酸钠（用作对照）和1在降低血糖和游离脂肪酸水平方面均有效。接受钼酸盐治疗的糖尿病大鼠在缺血后心脏功能方面表现出显著改善。关键词：钼、羟基吡喃酮、羟基吡啶酮、心脏功能。
• Biologically relevant O,S-donor compounds. Synthesis, molybdenum complexation and xanthine oxidase inhibition
  作者：Sílvia Chaves、Marco Gil、Sónia Canário、Ratomir Jelic、Maria João Romão、José Trincão、Eberhardt Herdtweck、Joana Sousa、Carmen Diniz、Paula Fresco、M. Amélia Santos

  DOI：10.1039/b717172b

  日期：——

  corresponding Mo(VI) complexes were studied both in solution and in the solid state, aimed at identifying the source of the biological properties. The solution studies showed that, in comparison with the O,O-analogues, the Mo(VI) complexes with the O,S-ligands present some stabilization, which is even more pronounced for the reduced Mo(IV) species. The crystal structures of the Mo(VI) complexes with

  两个O，S-供体配体，羟基硫吡喃酮 和 羟基硫代吡啶酮 开发和研究了衍生物，以及相应的 Ø，Ô衍生物，考虑到其潜在的药理应用，如黄嘌呤氧化酶（XO） 抑制剂。生物学分析表明，O，S-配体对XO具有很高的抑制活性（纳摩尔级，接近于XO）。制药业 药品 别嘌醇），与相应的O，O-类似物相反。由于这种生物医学意义钼含 酵素， 相应的 钼（VI）对复合物进行了溶液和固态研究，旨在鉴定其生物学特性的来源。解决方案研究表明，与O，O-类似物相比，钼（VI）与O，S-配体形成的配合物表现出一定的稳定性，对于还原钼（IV）物种。的晶体结构钼（VI） 与 羟基硫吡喃酮揭示了配位模式的良好灵活性，分别为单核和双核物种具有两种结构异构体和两种多晶型形式。这些结果为涉及XO相互作用的XO抑制的机理建议提供了支持。硫酮 团体 与 钼辅因子，从而表明 硫 原子在XO上有抑制作用。